Page 126 - Read Online

Page 16 of 16 Zanetto et al. Hepatoma Res 2018;4:70 I http://dx.doi.org/10.20517/2394-5079.2018.102

with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. Gastroenterology
2018;154:515-7.
87. Jühling F, Bandiera S, Hamdane N, Thumann C, Durand SC, et al. Hepatitis C virus-induced epigenetic and transcriptional changes persist
post cure. J Hepatol 2017;66:S21.
88. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
89. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, et al. A novel and validated prognostic index in hepatocellular carcinoma: the
inflammation based index (IBI). J Hepatol 2012;57:1013-20.
90. Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC
stage of hepatocellular carcinoma. J Hepatol 2017;66:338-46.
91. Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, et al. Immune inflammation indicators and implication for
immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016;7(41):67142-9.
92. Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, et al. Immune inflammation indicators and ALBI score to predict liver cancer
in HCV-patients treated with direct-acting antivirals. Dig Liver Dis 2018; doi: 10.1016/j.dld.2018.09.016.
93. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the
Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
94. Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C
cirrhosis. Aliment Pharmacol Ther 2016;43:1276-92.
95. Toniutto P, Zanetto A, Ferrarese A, Burra P. Current challenges and future directions for liver transplantation. Liver Int 2017;37:317-27.

96. Zeng QL, Li ZQ, Liang HX, Xu GH, Li CX, et al. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the
era of DAAs: too alarming? J Hepatol 2016;65:1068-9.
97. Carrat F. Clinical outcomes in HCV-infected patients treated with direct acting antivirals - 18-month post-treatment follow-up in the French
ANRS CO22 HEPATHER Cohort study. J Hepatol 2016;64:S215.
98. Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, et al. Among cirrhotic patients with a hepatitis C sustained viral response, the risk of
de-novo hepatocellular carcinoma relates to baseline factors and not the use of direct acting antivirals: results from a nationwide cohort. J
Hepatol 2017;66:S22-3.
99. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al. Occurrence of hepatocellular carcinoma in patients with hepatitis C virus
related liver disease treated with direct-acting antivirals. J Hepatol 2017;66:S23-4.
100. Issachar A, Sneh-Arbib O, Braun M, Shlomai A, Oxtrud E, et al. Occurrence and recurrence of malignancies post DAA Treatment in 5.1%
of patients- single center experience. J Hepatol 2017;66:S97.
101. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting
antiviral agents. Gastroenterology 2017;153:996-1005.e1.
102. Ogata F, Kobayashi M, Akuta N, Osawa M, Fujiyama S, et al. Outcome of all-oral direct-acting antiviral regimens on the rate of
development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease. Oncology 2017;93:92-
8.
103. Deterding K, Mauss S, Pathil A, Buggisch P, Schott E, et al. Long-term follow-up after IFN-free therapy of advanced HCV-associated
liver cirrhosis: continued improvement of liver function parameters – results from the German hepatitis C-registry (DHC-R). J Hepatol
2017;66:S55.
104. Finkelmeier F, Dultz G, Peiffer KH, Kronenberger B, Krauss F, et al. Risk of de novo hepatocellular carcinoma after HCV treatment with
direct-acting antivirals. Liver Cancer 2018;7:190-204.
105. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, et al. Direct-acting antivirals decreased tumor recurrence after initial
treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2017;62:2932-42.